Eliquis vs Repatha
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Eliquis | US Repatha | |
|---|---|---|
| Generic name | apixaban | evolocumab |
| Drug class | Factor Xa Inhibitor | PCSK9 Inhibitor (Biologic) |
| Treats | Blood clots, atrial fibrillation | High cholesterol, cardiovascular disease |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Bristol-Myers Squibb/Pfizer | Amgen |
| Year approved | 2012 | 2015 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $350M | $120M |
| Common side effects | Serious bleeding risk, Bruising easily, Prolonged bleeding from cuts, Blood in urine or stool | Injection site reactions, Allergic reactions, Back pain, Fatigue |
Frequently asked questions
Is Eliquis or Repatha better?
Neither is universally "better." Eliquis (apixaban) and Repatha (evolocumab) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Eliquis and Repatha?
Eliquis is a Factor Xa Inhibitor made by Bristol-Myers Squibb/Pfizer, while Repatha is a PCSK9 Inhibitor (Biologic) made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Eliquis has the larger estimated TV advertising budget of the two.